Metabolic Reprogramming in Hematologic Malignancies: Advances and Clinical Perspectives

17Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

Metabolic reprogramming is a hallmark of cancer progression. Metabolic activity supports tumorigenesis and tumor progression, allowing cells to uptake essential nutrients from the environment and use the nutrients to maintain viability and support proliferation. The metabolic pathways of malignant cells are altered to accommodate increased demand for energy, reducing equivalents, and biosynthetic precursors. Activated oncogenes coordinate with altered metabolism to control cell-autonomous pathways, which can lead to tumorigenesis when abnormalities accumulate. Clinical and preclinical studies have shown that targeting metabolic features of hematologic malignancies is an appealing therapeutic approach. This review provides a comprehensive overview of the mechanisms of metabolic reprogramming in hematologic malignancies and potential therapeutic strategies to target cancer metabolism.

Cite

CITATION STYLE

APA

Yu, Z., Zhou, X., & Wang, X. (2022, September 1). Metabolic Reprogramming in Hematologic Malignancies: Advances and Clinical Perspectives. Cancer Research. American Association for Cancer Research Inc. https://doi.org/10.1158/0008-5472.CAN-22-0917

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free